SENS.L

Sensyne Health
Sensyne Health PLC - Issue of New Ordinary Shares & Total Voting Rights
4th April 2022, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1083H
Sensyne Health PLC
04 April 2022
 

 

 

Sensyne Health plc


("Sensyne" or the "Company")

 

Issue of New Ordinary Shares and Total Voting Rights

 

Oxford, U.K. - 4 April 2022: Sensyne Health plc (LSE:SENS) ("Sensyne" or the "Company") today announces that it has issued a total of 236,625 new ordinary shares of ten pence nominal value ("New Ordinary Shares") to the US health systems St. Luke's University Health Network (St. Luke's) and Sentara Healthcare ("Sentara").

 

These New Ordinary Shares have been issued under the terms of the previously announced strategic research agreements (SRAs) and follow the completion of a valuation exercise as required under Section 593 of the Companies Act. 

 

Allocations were made as follows:

 

Health System

New Ordinary Shares Allocated

St Luke's

115,541

Sentara

121,084

Total

236,625

 

Application has been made to the London Stock Exchange for the admission of the 236,625 New Ordinary Shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on 7th April 2022.

 

Total Voting Rights

 

Following the allotment of the New Ordinary Shares, the total number of ordinary shares following admission will be 166,464,335 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore, following admission the total number of voting rights in Sensyne will be 166,464,335. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. 

 

-ENDS-

 

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

Contact details:

Sensyne Health


 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 


 

Liberum (Joint Broker)


Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications


Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290





 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUMGCUPPUAC ]]>
TwitterFacebookLinkedIn